Final Programme - iuphar

FC13 Maximising benefits and minimizing harms from
drugs
Wed 109 Relevance of manganese superoxide dismutase (SOD2 Val16Ala) and glutathione peroxidase1 (GPX1
Pro200Leu) functional polymorphisms in patients with idiosyncratic drug-induced liver injury (DILI)
Maribel Isabel Lucena, (Spain), E Garcia-Martin, RJ Andrade, C Martinez, C Stephens, JD Ruiz,
E Ulzurrun, MC Fernandez, JA Duran, A Melcon de Dios, Y Borraz, JAG Agundez
Wed 110 Introducing clinical events classification for improving antibiotic prescribing
Tatyana Lugovkina, (Russian Federation), B Richards
Wed 111 Usefulness of Bayes TDM for monitoring in immunosuppression using the Dynapred® platform:
An example with tacrolimus
John C Lukas, (Spain), I Oteo, R Calvo, A Valdivieso, N Leal, E Suarez
Wed 112 Impaired function of CYP2C9 metabolic enzyme and OATP1B1 transporter as a predisposition for
HMGCoA reductase inhibitors induced rhabdomyolysis:case reports
V Macolic-Sarinic, N Mirosevic-Skvrce, Nada Božina, (Croatia), S Marusic, S Tomic
Wed 113 The pharmacodynamics of single dose R- and S-warfarin when administered alone and in combination
as a function of VKORC1 genotype in healthy volunteers
John Maddison, (Australia), A Somogyi, B Jensen, M Gentgall, P Rolan
Wed 114 Inhibition of basal and ultraviolet B induced melanogenesis by cannabinoid receptors CB1
Sofia Magina, (Portugal), C Esteves Pinto, E Moura, MP Serrão, I Correia-de-Sá, D Moura,
M-A Vieira-Coelho
Wed 115 Protective effects of glutathione and the related thiols against hepatotoxicity of acetaminophen and
furosemide in mice
Yasuhiro Masubuchi, (Japan), J Nakayama, Y Sadakata
Wed 116 On expressing drug dosage
Mukul Mathur, (India), L Sharma, KK Sharma
Wed 117 Influence of VKORC1 polymorphism on PT-INR adherence to the target therapeutic range in long-term
warfarin therapy
Naoki Matsumoto, (Japan), M Watanabe, T Kumai, M Tanaka, Y Takeba, Y Harimoto, S Takenoshita,
Y Kinoshita, M Yamauchi, F Miyake, H Musha, S Kobayashi
Wed 118 Influence of Escherichia coli Nissle 1917 on cytochrome P450 protein expression in the intestine of
male rats
Zuzana Matuskova, (Czech Republic), A Tunkova, E Anzenbacherova, R Vecera,
H Tlaskalova-Hogenova, Z Zidek, P Anzenbacher
Wed 119 Incidence, genetic and non-genetic risk factors for severe phenprocoumon associated gastrointestinal
bleeding leading to hospitalisation
Karen May, (Germany), K Wergin, S Müller, M Hippius, K Farker, B Drewelow, J Szymanski,
D Rosskopf, PA Thürmann, W Siegmund
Wed 120 Effect of low-dose and high-dose aspirin on the pharmacokinetics and pharmacodynamics of edoxaban
Jeanne Mendell, (USA), S Chen, R Noveck, F Lee, V Petrushun, M Shi
Wed 121 Effect of naproxen on the pharmacokinetics and pharmacodynamics of edoxaban- encore abstract
Jeanne Mendell, (USA), S Chen, R Noveck, F Lee, V Petrushun, M Shi
Wed 122 The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban
pharmacokinetics and pharmacodynamics
Jeanne Mendell, (USA), R Noveck, H Zahir, F Lee, V Petrushun, I Rubets, G Zhang, M Shi, S Chen
Wednesday 21 July ■ 13:00 - 14:00 ■ Poster Area 253